Eiko Lifesciences acquires 25% stake in API-maker Reflux Pharma
Thane-headquartered Eiko LifeSciences Ltd (ELL) has acquired a 25.01 % stake in Navi Mumbai-headquartered Reflux Pharmaceuticals Pvt Ltd (RPPL) which manufactures and exports active pharmaceutical ingredients (APIs) and intermediates. The acquisition will help ELL to leverage its expertise in specialty chemicals and its global network to enter the lucrative European markets, where RPPL has a strong presence.
Want to receive such news items in your inbox? Click Here to sign up for a trial.